Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LONDON and CARLSBAD, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization...
-
LONDON and CARLSBAD, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and...
-
LONDON and CARLSBAD, Calif., Feb. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and...
-
- Total preliminary net product sales of approximately $108 million for the fourth quarter and approximately $309 million for the full year - - Total Epidiolex® preliminary net product sales of...
-
LONDON and CARLSBAD, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and...
-
CARLSBAD, Calif., Dec. 07, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines,...
-
LONDON and CARLSBAD, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription...
-
CARLSBAD, Calif., Nov. 22, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the...
-
GW also welcomes the positive guideline recommendation for Sativex® (nabiximols) for the treatment of spasticity due to multiple sclerosis as part of NICE’s evaluation of cannabis-based medicinal...
-
GW also welcomes the positive guideline recommendation for Sativex® (nabiximols) for the treatment of spasticity due to multiple sclerosis as part of NICE’s evaluation of cannabis-based medicinal...